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Background: The goal of this study was to determine the prognostic factors associated with an improved overall
outcome after stereotactic body radiotherapy (SBRT) for primary lung cancer and metastatic lung tumors.
Methods: A total of 229 lung tumors in 201 patients were included in the study. SBRT of 45 Gy in 3 fractions, 48 Gy
in 4 fractions, 60 Gy in 8 fractions or 60 Gy in 15 fractions was typically used to treat 172 primary lungs cancer in
164 patients and 57 metastatic lung tumors in 37 patients between January 2001 and December 2011. Prognostic
factors for local control (LC) and overall survival (OS) were analyzed using a Cox proportional hazards model.
Results: The median biologically effective dose was 105.6 Gy based on alpha/beta = 10 (BED10). The median
follow-up period was 41.9 months. The 3-year LC and OS rates were 72.5% and 60.9%, and the 5-year LC and OS
rates were 67.8% and 38.1%, respectively. Radiation pneumonitis of grades 2, 3 and 5 occurred in 22 petients,
6 patients and 1 patient, respectively. Multivariate analyses revealed that tumor origin (primary lung cancer or
metastatic lung tumor, p < 0.001), tumor diameter (p = 0.005), BED10 (p = 0.029) and date of treatment (p = 0.011)
were significant independent predictors for LC and that gender (p = 0.012), tumor origin (p = 0.001) and tumor
diameter (p < 0.001) were significant independent predictors for OS.
Conclusions: SBRT resulted in good LC and tolerable treatment-related toxicities. Tumor origin and tumor diameter
are significant independent predictors for both overall survival and local control.
Keywords: Stereotactic radiotherapy, SBRT, Primary lung cancer, Metastatic lung tumor, Oligometastasis,
Prognostic factorBackground
Stereotactic body radiotherapy (SBRT) results in a high
local control rate for relatively small lung tumors and
has low treatment-related toxicity, and it thus has many
benefits for patients, especially patients who cannot
undergo surgery [1-3]. SBRT may also be beneficial for
patients who choose not to undergo surgery. For exam-
ple, elderly patients, even elderly patients with no or
only a few comorbidities and moderate lung function,
often hesitate to undergo surgery because of concerns* Correspondence: t.yamamoto@rad.med.tohoku.ac.jp
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article, unless otherwise stated.about postoperative complications, decline in activities
of daily living, and progression of dementia, even in
short-term admission. A time-trend analysis in the
Netherlands showed that the number of elderly patients
treated with radiotherapy for stage I non-small-cell lung
cancer (NSCLC) has been increasing over time. This has
occurred in parallel with increased availability of SBRT
and has led to a decrease in untreated patients and no
increase in surgically treated patients, despite operative
and perioperative advances such as video-assisted tho-
racic surgery [4]. Furthermore, the outcome for stage I
NSCLC treated with SBRT is now close to that after
lobectomy, based on the results of a recent propensity-
score matched analysis [5].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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SBRT for oligometastatic lung tumors have shown 2- to
3-year survival rates with good local control (LC) that
compare favorably with surgical results [2,3]. If SBRT
has an efficacy comparable to that of tumor resection,
this technique may provide patients with a better quality
of life, shorter time away from work, and minimal inter-
ruption of other treatment. This third issue may be a
major advantage because systemic chemotherapy is often
performed for targeting oligometastatic lung tumors,
treating another lesion, or as maintenance or consolida-
tion therapy for potential metastases.
Recently, the new notion of oligo-recurrence was pro-
posed because the initial concept of oligometastases did
not eliminate the uncontrolled primary site with several
distant metastases. Oligo-recurrence has been suggested
as a state of metachronous limited recurrence or metas-
tases possibly cured with local therapy [6]. SBRT for
lung oligo-recurrence with good LC rate and survival
rate has also been reported [7].
Many prognostic factors for LC after SBRT have been
reported, including tumor diameter, standardized uptake
value (SUV) on [18F]fluorodeoxyglucose positron emis-
sion tomography (FDG-PET), low dose distribution,Table 1 Baseline patient characteristics
Primary lung cancer
Number 164 patients












< 37.5 35 (21%)
≥ 37.5 88 (55%)
FEV1, % of predicted
< 92 54 (47%)
≥ 92 60 (52%)




Abbreviations: ECOG Eastern cooperative oncology group, FEV1 forced expiratory vometastatic lung tumors, and colorectal lung metastases
[8-14]. In contrast, there have been only a few studies in
which prognostic factors for overall survival (OS) were
examined, though clarification of such factors is impor-
tant to maximize the benefit/toxicity ratio [14-17]. In
this study, we retrospectively reviewed our results for
lung tumors treated with SBRT with the goal of identi-
fying prognostic factors associated with LC and OS and
thus establishing a strategy for balancing the benefits
and risks in use of SBRT.
Methods
Patients
A review of our institutional clinical database identified
215 patients who were treated with SBRT at our institute
between January 2001 and December 2011. Patients with
follow-up of < 3 months were excluded, leaving a total of
229 lung tumors in 201 patients that were analyzed
retrospectively. Of these, 172 tumors in 164 patients
were stage I primary lung cancer and 57 tumors in 37
patients were metastatic tumors. The main clinical and
pathological pretreatment features are summarized in
Tables 1 and 2. All numerical data are expressed as me-
dians. The histological diagnoses of the 172 cases ofMetastatic lung tumor Total
37 patients 201 patients
63 (range: 25–85) 76 (range: 25–92)
13 (35%) 52 (25%)
24 (64%) 149 (74%)
37 (100%) 179 (89%)
0 (0%) 22 (10%)
6 (16%) 87 (43%)
31 (83%) 114 (56%)
Median 37.5 (range: 0–180)
10 (43%) 45 (24%)
10 (43%) 45 (24%)
5 (20%) 93 (50%)
Median 92.5 (range: 25.1-203.6)
4 (66%) 58 (48%)
2 (33%) 62 (51%)
0 13 (6%)
20 (54%) 84 (41%)
17 (45%) 117 (58%)
lume in 1 second.
Table 2 Baseline tumor and treatment characteristics
Primary lung cancer Metastatic lung tumor Total
Number 172 tumors 57 tumors 229 tumors
Tumor diameter (cm) 2.2 (range: 0.9-4.7)
≤ 2.0 73 (42%) 27 (47%) 100 (43%)
2.1-3.0 75 (43%) 23 (40%) 98 (42%)
3.1-5.0 24 (13%) 7 (12%) 31 (13%)
Tumor appearance
Mainly solid component 160 (93%) 57 (100%) 217 (94%)
Mainly ground-glass opacity 12 (6%) 0 (0%) 12 (5%)
SUVmax on staging FDG-PET 5.9 (range: 0.6-22.8)
< 5.9 53 (50%) 4 (57%) 57 (50%)
≥ 5.9 53 (50%) 3 (42%) 56 (50%)
Prescription dose
BED10≤ 105 Gy 84 (48%) 12 (21%) 96 (41%)
BED10 > 105 Gy 88 (51%) 45 (78%) 133 (58%)
Date of treatment
2001-2005 76 (44%) 39 (68%) 115 (50%)
2006-2011 96 (55%) 18 (31%) 114 (50%)
Abbreviations: SUVmax maximum standardized uptake value, FDG-PET [18F]fluorodeoxyglucose positron emission tomography, BED10 biological effective dose
calculated using α/β = 10.
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squamous cell carcinoma (40 tumors), large cell carcin-
oma (10 tumors), small cell carcinoma (2 tumors), NSCLC
not otherwise specified (5 tumors), and bronchioloalveolar
carcinoma (2 tumors), and 57 tumors were pathologically
unproven. A metastatic lung tumor was defined as the
appearance of a solid tumor during follow-up after treat-
ment for the primary lesion. Inclusion criteria of meta-
static tumors were that tumor diameter was 5 cm or less,
both radiation oncologists and the physician assessed that
SBRT of metastatic tumors would yield improved systemic
control and prolonged survival, and consequently, all
of the primary sites were controlled. Thirty-five cases
were surgically resected, one case was esophageal cancer
controlled by chemoradiation and another case was hepa-
tocellular carcinoma controlled by transarterial chemoem-
bolization. Two cases were synchronous metastases with a
primary lesion, and 6 cases received additional chemother-
apy. Biopsy for a metastatic lung tumor was performed
only during follow-up of double cancer. Of the 57 meta-
static tumors, 29 were metastases from colorectal cancer
and 28 were metastases from other malignancies.
SBRT procedure
We previously reported details of our SBRT technique
and follow-up studies in patients with primary lung can-
cer [18]. Each patient was immobilized in a body frame
(Vac-loc, Med-tek) and a clinician observed the respira-
tory tumor motion on a simulator (Ximatron, VarianMedical Systems). If breathing motion had a large effect
on the tumor location, the clinician made the decision
of whether to use an abdominal pressure belt, taking co-
morbidity and performance status into account. Treat-
ment planning was then performed in the same position,
using slow-rotation serial CT scanning (slice thickness,
2.5 mm; 4 s/slice). The gross tumor volume was defined
as the visible extent of the tumor on the CT image in
the lung window. The internal target volume (ITV) was
determined from the slow-rotation CT images and from
respiratory tumor motion on the simulator. The plan-
ning target volume was defined as the ITV with a 5-mm
margin for set-up uncertainty. The SBRT plan was cre-
ated with a 3D radiotherapy planning system (CADPlan/
Eclipse, Varian Medical Systems). SBRT was delivered
with a linear accelerator (Clinac 23EX, Varian Medical
Systems) using 6 MV X-ray beams with 5 to 7 non-
coplanar multistatic ports and/or multidynamic arcs.
Before June 2009, the dose calculation algorithm was
based on the pencil beam method with heterogeneity
correction (modified Batho power law), and 45 Gy in 3
fractions, 48 Gy in 4 fractions, 60 Gy in 8 fractions, or
60 Gy in 15 fractions to the isocenter was prescribed. In
February 2004, we changed the prescription dose from
45 Gy in 3 fractions to 48 Gy in 4 fractions to unify the
dose for the Japan clinical trial series. After June 2009,
the dose calculation algorithm was changed to an ana-
lytical anisotropic algorithm and 40 Gy in 4 fractions or
50 Gy in 8 fractions covering 95% of the PTV (D95) was
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pencil beam convolution were 46.5 Gy (range: 43.2-
50.7 Gy) in 4 fractions and 56.2 Gy (range: 55.3-61.7 Gy)
in 8 fractions. The choice of dose depended on tumor
location and performance status: 60 Gy in 8 fractions,
60 Gy in 15 fractions or 50 Gy in 8 fractions was
selected if the lung tumor was adjacent to critical struc-
tures such as the main bronchus, heart and great vessels,
esophagus or stomach. Dose escalation was not per-
formed for larger tumors or metastatic tumors. This
study was approved by the ethical committee of Tohoku
University Hospital and informed consent was obtained
from all patients.
Follow-up after SBRT
A clinical examination by a radiation oncologist and CT
scanning were performed 4–6 weeks after SBRT to as-
sess the pulmonary response. Thereafter, patients un-
derwent follow-up examinations every 3–6 months for
2 years and then every 6 months after 2 years. Patients
also underwent examinations by doctors in charge of the
primary disease. Local recurrence or local failure was de-
fined as local progression to ≥ 1.5 times the dimensions
of the original tumor [18]. FDG-PET was sometimes
performed to distinguish local recurrence from dense
consolidation. The final diagnosis of local recurrence
was made by physicians and radiation oncologists.
Statistical analysis
Time to an event was calculated from the first day of
SBRT to the day an event was confirmed. Statistical ana-
lyses were performed using JMP v. 10.0.2 (SAS Institute).
Cumulative LC and OS rates were calculated using
Kaplan-Meier curves, and a log-rank test was used to
compare the curves. To analyze prognostic factors, univar-
iate and multivariate analyses were performed using a Cox
proportional hazards model. In these analyses, continuous
variables that included missing values, such as SUVmax
and pack-years smoking, were discretely divided at the
sample median and then analyzed as categorical variables.
Correlation coefficients for all variables were calculated to
avoid multicollinearity. P < 0.05 was defined as significant
in all tests. For analysis of various dosing schedules, the
biological effective dose (BED10) was calculated using the
following formula: BED10 = nd [1 + d/(α/β)], where n is
the number of fractions, d is the isocenter dose per frac-
tion, and α/β ratio is 10 Gy for the tumor. Toxicity was
graded using the National Cancer Institute Common Ter-
minology Criteria for Adverse Events ver. 4.0.
Results
Treatment results
The median follow-up period for all patients was
35.0 months (range: 3.3-115.6 months) and that forsurvivors was 41.9 months (range: 3.3-105.2 months). All
of the primary sites with metastatic lung tumors were
controlled at the time SBRT was started. During follow-
up, local recurrence was observed in 54 of the 229 tumors.
The median time to local failure was 14.9 months (range:
4.0-66.9 months). None the 12 tumors with mainly
ground-glass components showed local failure; therefore,
we had to exclude this factor from the analysis. Of the 201
patients, 77 died of the primary disease and 38 died of
other causes. The median survival period was 43.1 months
and the median cause-specific survival period was 65.6
months. The 3-year LC, cause-specific survival (CSS) and
OS rates were 72.5% (95% confidence interval [CI]: 65.3-
78.8), 70.2% (95% CI: 62.8-76.6) and 60.9% (95% CI: 53.6-
67.7), respectively. The respective 5-year rates were 67.8%
(95% CI: 59.6-75.1), 51.7% (95% CI: 42.8-60.5) and 38.1%
(95% CI: 30.3-46.5) (Figure 1). There was a significant dif-
ference in LC between the primary lung cancer curve and
metastatic lung tumors curve (p = 0.010, log-rank test)
(Figure 2).
Radiation pneumonitis of grades 2 and 3 occurred in 22
and 6 patients, respectively. Steroids were administered to
14 patients. Grade 5 radiation pneumonitis occurred in
one patient who had pathologically proven interstitial
pneumonia before SBRT. The interstitial pneumonia was
exacerbated after SBRT and then fatal bacterial pneumo-
nia were involved in.
Univariate and multivariate analyses
The results of univariate and multivariate analyses for LC
and OS are shown in Tables 3 and 4. In univariate ana-
lysis, tumor origin (primary lung cancer vs. metastatic
lung tumors; p = 0.017, hazard ratio [HR]: 0.48, 95% CI:
0.27-0.87), tumor diameter (per 1 cm increase; p < 0.001,
HR: 1.87, 95% CI: 1.35-2.57), SUVmax (≥ 5.9 vs. < 5.9;
p = 0.042, HR: 2.21, 95% CI: 1.02-5.03), date of treatment
(2001–2005 vs. 2006–2011; p = 0.019, HR: 1.91, 95% CI:
1.11-3.39) and prescription dose (BED10: > 105 Gy
vs. ≤ 105 Gy; p = 0.038, HR: 0.56, 95% CI: 0.32-0.96) were
significant predictors for LC; and gender (female vs. male;
p = 0.005, HR: 0.53, 95% CI: 0.33-0.83), tumor origin (pri-
mary lung cancer vs. metastatic lung tumors; p = 0.017,
HR: 0.48, 95% CI: 0.27-0.87), tumor diameter (per 1 cm
increase; p < 0.001, HR: 1.70, 95% CI: 1.33-2.16) and SUV-
max (≥ 5.9 vs. < 5.9; p = 0.004, HR: 2.12, 95% CI: 1.26-
3.64) were significant predictors for OS. In multivariate
analysis, tumor origin (primary lung cancer vs. metastatic
lung tumors; p < 0.001, HR: 0.21, 95% CI: 0.09-0.47),
tumor diameter (per 1 cm increase; p = 0.005, HR: 1.70,
95% CI: 1.17-2.45) and prescription dose (BED10: > 105 Gy
vs. ≤ 105 Gy; p = 0.029, HR: 0.51, 95% CI: 0.27-0.93)
were significant independent predictors for LC; and gen-
der (female vs. male; p = 0.012, HR: 0.56, 95% CI: 0.34-
0.88), tumor origin (primary lung cancer vs. metastatic
Figure 1 Curves of (a) LC rate and (b) CSS and OS. (a) Local control (LC) rate and (b) cause-specific survival (CSS) and overall survival (OS) in
all patients in the study (Kaplan-Meier method).
Yamamoto et al. BMC Cancer 2014, 14:464 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/464lung tumors; p = 0.001, HR: 0.45, 95% CI: 0.28-0.73) and
tumor diameter (per 1 cm increase; p < 0.001, HR: 1.70,
95% CI: 1.30-2.21) were significant independent predic-
tors for OS.
Subgroup analysis of metastasis from colorectal cancer
The results of a subanalysis comparing patients with me-
tastases from colorectal cancer and non-colorectal can-
cer are shown in Figure 3. The difference in LC between
the two subgroups was significant (p = 0.022).
Discussion
This study was performed as a review of a single center
experience of SBRT for lung tumors. In multivariate ana-
lysis, metastatic lung tumors, increased tumor size, earlydate of treatment and prescription dose of BED10 >
105 Gy were significant factors for unfavorable LC. LC
itself was associated with OS in univariate analysis
(HR: 2.02, 95% CI: 1.33-3.01, p = 0.001), indicating that a
strategy for improving LC is important. For this purpose,
dose escalation may be reasonable for metastatic lung
tumors or larger tumors, given the relatively low toxicity
in our patients, despite the poor pulmonary background
and the presence of complications. However, this strat-
egy may not be applicable in all cases and may not
always give the expected outcome because critical struc-
tures can prevent delivery and distribution of a sufficient
dose. This problem is also likely to be increased in dose
escalation for larger tumors or multiple metastatic
tumors.
Figure 2 Analysis comparing local control rate with primary lung cancer and metastatic lung tumors. There was a significant difference in
LC between primary lung cancer and metastatic lung tumors (p = 0.010, log-rank test).
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categories at the sample median (> 105 Gy, ≤ 105 Gy),
was an independent predictor. The results confirmed pre-
vious findings [8,14]. Prescription dose ≤ 105 Gy was often
used when the target was close to a critical structure.
Thus, this strategy was relatively safe but might contributeTable 3 Univariate analysis for local control (LC) and overall s
Variables UVA
HR
Age (per 10-y increase) 0.95
Gender (female vs. male) 0.66
Performance status (0–1 vs. ≥ 2) 1.19
Tumor origin (primary lung cancer vs. metastatic lung tumors) 0.48
History of other malignancies (yes vs. no) 0.70
Pack-year smoking (≥ 37.5 vs. < 37.5) 1.38
Operability (operable vs. inoperable) 0.68
FEV1, % of predicted (≥ 92% vs. < 92%) 1.01
Tumor diameter (per 1 cm increase) 1.87
SUVmax (≥ 5.9 vs. < 5.9) 2.21
Date of treatment (2001–2005 vs. 2006–2011) 1.91
Prescription dose (BED10: > 105 Gy vs. ≤ 105 Gy) 0.56
Radiation pneumonitis (≥ 2 vs. < 2) 0.85
Abbreviations: UVA univariate analysis, LC local control, OS overall survival, HR hazar
SUVmax maximum standardized uptake value, BED10 biological effective dose calcuto relatively low LC rate because of the low prescription
dose.
The date of treatment was a significant factor for LC,
possibly due to improvements in contouring (including
spiculation of the GTV) and radiation planning (intro-
duction of the concept of the homogeneity index).urvival (OS)
for LC UVA for OS
(95% CI) P value HR (95% CI) P value
(0.80-1.15) 0.617 0.93 (0.80-1.11) 0.428
(0.34-1.19) 0.177 0.53 (0.33-0.83) 0.005*
(0.52-3.43) 0.703 0.86 (0.50-1.58) 0.619
(0.27-0.87) 0.017* 0.53 (0.34-0.84) 0.007*
0.38-1.21) 0.212 0.83 (0.56-1.20) 0.331
(0.77-2.51) 0.266 0.85 (0.57-1.26) 0.426
(0.38-1.19) 0.185 0.76 (0.52-1.12) 0.173
(0.49-2.05) 0.972 0.84 (0.51-1.36) 0.494
(1.35-2.57) <0.001* 1.70 (1.33-2.16) <0.001*
(1.02-5.03) 0.042* 2.12 (1.26-3.64) 0.004*
(1.11-3.39) 0.019* 1.36 (0.93-1.99) 0.106
(0.32-0.96) 0.038* 0.94 (0.65-1.37) 0.760
(0.34-1.78) 0.689 0.72 (0.40-1.22) 0.225
d ratio, CI confidence interval, FEV1 forced expiratory volume in 1 second,
lated using α/β = 10. *p < 0.05.
Table 4 Multivariate analysis for local control (LC) and overall survival (OS)
Variables MVA for LC MVA for OS
HR (95% CI) P value HR (95% CI) P value
Gender (female vs. male) n.s. 0.56 (0.34-0.88) 0.012*
Tumor origin (primary vs. metastatic lung tumors) 0.21 (0.09-0.47) <0.001* 0.45 (0.28-0.73) 0.001*
Tumor diameter (per 1 cm increase) 1.70 (1.17-2.45) 0.005* 1.70 (1.30-2.21) <0.001*
SUVmax (≥ 5.9 vs. < 5.9) 1.50 (0.66-3.61) 0.331 1.41 (0.81-2.48) 0.218
Prescription dose (BED10: > 105 Gy vs. ≤ 105 Gy) 0.51 (0.27-0.93) 0.029* n.s
Date of treatment (2001–2005 vs. 2006–2011) 2.22 (1.19-4.23) 0.011* n.s
Abbreviations: MVA multivariate analysis, LC local control, OS overall survival, HR hazard ratio, CI confidence interval, SUVmax maximum standardized uptake value,
BED10 biological effective dose calculated using α/β = 10; n.s. not significant. *p < 0.05.
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follow-up period became longer. The median follow-up
periods in 2001–2005 and 2006–2011 were 50.2 months
and 41.6 months, respectively, and this difference would
also therefore affect the results.
We found that a metastatic lung tumor was an inde-
pendent poor prognostic factor for LC and OS. For LC,
this result confirms a previous finding of Hamamoto
et al. [13] and is based on a much longer follow-up
period in the current study.
The poor LC rate of a metastatic lung tumor may be
the result of formation of a metastasis. Metastatic tumor
cells are the particularly potent malignancy of tumor,Figure 3 Subanalysis comparing patients with metastases from colore
local control between subgroups with metastases from colorectal cancer awhich are the most aggressive cells in the neoplasm
because most malignant cells entering the metastatic
process are killed, especially in the blood circulatory sys-
tem [19]. Also, in some cases, adjuvant chemotherapy or
hormonal therapy is performed after surgery. Cells with
high metastatic potential are resistant to this treatment
based on genetic instability due to a several-fold increase
in the rate of mutation compared to tumor cells with
lower metastatic potential [20]. This genetic instability
increases the angiogenic and invasive potential of tumor
cells, and the tumor cells escape from immune surveil-
lance, thus increasing the chance of metastasis. Through
these steps, and after formation of a metastasis, tumorsctal and non-colorectal cancer. There was a significant difference in
nd metastases from noncolorectal disease (p = 0.022, log-rank test).
Yamamoto et al. BMC Cancer 2014, 14:464 Page 8 of 10
http://www.biomedcentral.com/1471-2407/14/464in advanced stages develop biological heterogeneity and
increased radioresistance before and during SBRT.
Another reason for the poor LC rate of a metastatic lung
tumor might be the state of the patient. The effects of dis-
ease treatment and disease progression may lead to cach-
exia and anemia temporarily or throughout the course of
the disease, making the tumor more hypoxemic. Tumor
hypoxemia has been hypothesized to lead to tumor
growth and resistance to therapy because of induction of
angiogenesis, genetic mutations, resistance to apoptosis,
and resistance to free radicals from radiotherapy [21].
These changes may be one of the reasons for the poor LC
of metastatic lung tumors, but both the “seed” aspect and
the “soil” aspect may be important. According to the “seed
and soil” hypothesis, metastasis is the product of interac-
tions between selected cancer cells (the “seeds”) and spe-
cific organ microenvironments (the “soil”) [22]. In the
lung environment, stromal products cause upregulation of
P-glycoprotein in the cells, which prompts excretion of a
variety of toxic compounds, including chemotherapeutic
drugs, resulting in enhanced resistance to drugs [23].
Similarly, through tumor-stroma interactions, some stro-
mal products may cause increased radioresistance of
metastatic cells. If a microenvironment is changed to a
rich soil due to interactions and molecular factors, circu-
lating tumor cells may be reseeded, as at the primary site
[24]. Therefore, modulation of a tumor microenvironment
using approaches such as antiangiogenic therapy may be
effective in some metastatic cases.
In subgroup analysis, metastases from colorectal can-
cer showed a lower local control curve than did metasta-
ses from non-colorectal cancer, consistent with previous
findings [12]. However, we cannot conclude that colo-
rectal metastases are more radioresistant than other me-
tastases because of the small sample size and the variety
of non-colorectal tumors, given that malignant diseases
have various natural histories. For example, our cases
included two cases of metastasis from thyroid cancer,
which generally shows slow growth. Our findings do
suggest that metastases from colorectal cancer are ag-
gressive and are likely to cause short-term local relapse.
Although our inclusion criteria for metastatic lung tu-
mors included both oligometastasis and oligo-recurrence,
SBRT as a local therapy might be effective in both situa-
tions. According to the Norton-Simon hypothesis, the effi-
cacy of chemotherapy is proportional to the growth rate
of the tumor, and the growth is faster when the tumor is
not bulky. Therefore, treatment of a bulky tumor with a
slower growth rate and thus lower sensitivity to chemo-
therapy might make the remaining tumor cells more sen-
sitive to chemotherapy [25,26]. Improvement in LC by
reducing metastases should lead to increased OS for
patients including both patients with oligometastasis and
patients with oligo-recurrence.Tumor diameter was identified as an independent factor
for OS in multivariate analysis. This was probably due to
the poor LC of a large tumor and the increased tendency
for metastasis. In pulmonary resection with node dissec-
tion for clinical stage I NSCLC, 19.4% of the patients were
found to have pathologically positive nodes, with a par-
ticularly high rate of 31.8% for unexpected positive nodes
in clinical stage IB cases [27]. Thus, this analysis showed
that tumor size and solid consistency were independent
predictors for node metastasis but did not show that un-
expected pathologically positive nodes affected OS. How-
ever, in our analysis of stage I NSCLC cases, clinical hilar
lymph node or mediastinal lymph node failure was a sig-
nificant factor for unfavorable OS (HR: 1.73, 95% CI: 1.04-
2.78, p = 0.034). This finding suggests that staging must be
performed thoroughly before SBRT. In an operable case,
assessment of suspicious lymph nodes by endoscopic
ultrasound-guided fine-needle aspiration may be neces-
sary. Adjunct therapy for a larger tumor should also be
considered in cases in which this is possible.
Female gender was also found to be a favorable factor
for OS but not for LC. This may be because smoking was
less common in females, and this may reduce smoking-
related complications and development of another malig-
nancy. Also, epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) therapy for primary lung
cancer with EGFR mutation was more common in fe-
males, with 6 of 16 female patients (37%) receiving an
EGFR-TKI in the course of treatment, in contrast to only
2 of 66 male patients (3%).
Analysis of tumor consistency was not included in the
study because there was no local failure of ground-grass
opacity (GGO) tumors and there was only one case in
which disease progression occurred. Most tumors with
mainly a GGO component were atypical adenomatous
hyperplasia, adenocarcinoma in situ (formerly referred
to as bronchioloalveolar carcinoma) or minimally inva-
sive adenocarcinoma, all of which have a relatively good
prognosis [28]. Thus, assessment of GGO tumors will
require more cases and longer follow-up periods. How-
ever, it may be more useful to examine the safety of
treating multiple sites by SBRT. Tumors with mainly a
GGO component are often multifocal, and for all such
tumors (not limited to GGO tumors), the lifetime inci-
dence of a second primary tumor after surgical resection
is > 10% [29]. More cases of multi-site treatment should
emerge as the outcome of SBRT improves, and this will
allow an evaluation of the safety of repetitive treatment
with SBRT.
There were several limitations to this study. First, this
study was a retrospective single institute analysis with
a limited sample size, the number of metastatic lung tu-
mors being particularly small. Second, various treatment
protocols were included in the analysis. There were a
Yamamoto et al. BMC Cancer 2014, 14:464 Page 9 of 10
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fractionation schema.
Conclusions
SBRT gave a high local control rate with tolerable treat-
ment-related toxicities. Our results suggest that dose es-
calation should be considered for larger and/or metastatic
lung tumors to improve the balance of benefits and risks
of SBRT and to obtain better overall survival.
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